BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Profitability
This table compares BioMarin Pharmaceutical and Genelux’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioMarin Pharmaceutical | -0.52% | 5.58% | 3.51% |
| Genelux | N/A | -205.85% | -138.79% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for BioMarin Pharmaceutical and Genelux, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 3 | 2.80 |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
BioMarin Pharmaceutical currently has a consensus target price of $87.91, suggesting a potential upside of 56.90%. Genelux has a consensus target price of $20.00, suggesting a potential upside of 920.41%. Given Genelux’s higher possible upside, analysts plainly believe Genelux is more favorable than BioMarin Pharmaceutical.
Volatility & Risk
BioMarin Pharmaceutical has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Genelux has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Institutional & Insider Ownership
98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares BioMarin Pharmaceutical and Genelux”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioMarin Pharmaceutical | $3.22 billion | 3.37 | $348.90 million | ($0.10) | -560.30 |
| Genelux | $8,000.00 | 11,085.02 | -$32.15 million | ($0.86) | -2.28 |
BioMarin Pharmaceutical has higher revenue and earnings than Genelux. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Genelux on 9 of the 15 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
